Name | Type | Description | Interventions |
---|
Arm A (Phase II Randomization): Polatuzumab+BR in FL | Experimental | Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL. | - Bendamustine
- Polatuzumab vedotin
- Rituximab
|
Arm B (Phase II Randomization): BR in FL | Active Comparator | Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL. | |
Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL | Experimental | Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL. | - Bendamustine
- Polatuzumab vedotin
- Rituximab
|
Arm D (Phase II Randomization): BR in DLBCL | Active Comparator | Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL. | |
Arm E (Phase II Expansion): Polatuzumab+BG in FL | Experimental | Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL. | - Bendamustine
- Obinutuzumab
- Polatuzumab vedotin
|
Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL | Experimental | Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL. | - Bendamustine
- Obinutuzumab
- Polatuzumab vedotin
|
Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL | Experimental | Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL for up to 6 cycles. | - Bendamustine
- Polatuzumab vedotin
- Rituximab
|
Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL | Experimental | Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL for up to 6 cycles. | - Bendamustine
- Polatuzumab vedotin
- Rituximab
|
Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL | Experimental | Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL for up to 6 cycles. | - Bendamustine
- Obinutuzumab
- Polatuzumab vedotin
|
Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL | Experimental | Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL for up to 6 cycles. | - Bendamustine
- Obinutuzumab
- Polatuzumab vedotin
|